Squamous Non-Small Cell Lung Cancer: Advancing Treatment Strategies Through Leveraging Complex Disease Biology
Mark A. Socinski, MD
Executive Medical Director
Florida Hospital Cancer Institute
Member, Thoracic Oncology Program
This case-based enduring activity will cover the long-term treatment and management of patients with lung cancer.
This activity is designed to meet the educational needs of oncologists, oncology nurses, pathologists, radiologists, pharmacists, and other healthcare practitioners who care for patients with lung cancer.
Upon completion of the program, attendees should be able to:
- Review the histologic, pathologic, immunologic and epidemiologic characteristics of squamous non-small cell lung cancer
- Discuss current data for the individualized selection of combination therapies for the first-line treatment of patients with advanced or metastatic, squamous NSCLC
- Apply clinical trial data from studies of advanced squamous NSCLC in support of subsequent lines of treatment in patients who have progressed through first-line therapy
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the long-term treatment and management of patients with NSCLC.
0.5 ANCC Contact Hour(s)
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 0.5 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME)
Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Mark A. Socinski, MD, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Genentech, BMS, Spectrum and Pfizer. Dr. Socinski also sits on the speaker’s bureau for Astra Zeneca, Celgene, Genentech, BMS and Lilly.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Ana Goffin, MPA, Program Manager for Med Learning Group has nothing to disclose.
Nina Oshio MS, Pharma D, Medical Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the activity.
3. Submit the evaluation form to Med Learning Group.
You will receive your certificate via email within 30 days.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at firstname.lastname@example.org.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
RELEASE DATE: April 3, 2018
EXPIRATION DATE: April 3, 2019
This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields. This subsidy is reflected in the registration fees for this activity.
Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.